$SRXH

SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)

SRX Global Inc. (NYSE American: SRXH) reported preliminary balance sheet metrics after its EMJX acquisition and a July 6, 2026 reverse stock split. As of June 30, 2026, it estimated NAV of about $60 million, or $3.07 per share, with roughly $40 million cash, over $15 million short-term investments, and no debt. Shares outstanding were about 19.52 million.

Original reporting
Published Jul 8, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 6:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1) — source image
Decision brief

The 30-second read

$SRXHBullishMed
01

Why it matters

The key decision-relevant items are per-share NAV, cash and short-term investment levels, and the claim of no outstanding debt, which together inform solvency and valuation framing until the 10-Q.

02

Market read

Traders can reassess SRXH’s liquidity and per-share valuation using the disclosed preliminary NAV and cash/short-term investment totals, but should wait for confirmation in the upcoming 10-Q.

03

What to watch

NAV includes estimated total assets and liabilities and may be sensitive to valuation of non-cash items (e.g., digital assets) and quarter-end adjustments; the reverse split can also affect liquidity and trading dynamics.

Relevance 6/10Novelty 6/10Timing: ahead of the company’s 10-Q filing expected on or before Aug 14, 2026

Background

SRXH says it completed the EMJX acquisition and effectuated a July 6, 2026 share consolidation (one-for-sixty reverse split), then provided a preliminary balance-sheet update.

Company-level read

Ticker impact

$SRXHBullishMedium confidence
Context

SRXH reports preliminary NAV of about $3.07/share, ~$40M cash plus ~$15M short-term investments, and no debt after its EMJX acquisition and July 6 reverse split.

Expected impact

Likely modest positive bias as the market prices in stronger liquidity and elimination of debt, though magnitude is uncertain until the 10-Q.

Evidence & confidence

The release provides concrete preliminary metrics (NAV, cash, short-term investments, no debt) and share count after a reverse split, which are directly relevant to per-share valuation and solvency. However, it is explicitly preliminary and unaudited, so follow-through depends on the upcoming 10-Q.

Market effects

Limited read-across; this is a microcap-style balance-sheet and capital-structure update rather than a sector-wide signal.

None material indicated.

None indicated.

Counterpoint

Because the figures are preliminary and unaudited, the market may discount them until the quarter-end close and 10-Q confirm asset quality and liabilities.

Key entities

  • SRX Global Inc.

    Subject of the press release, providing preliminary NAV and capitalization metrics after EMJX acquisition and reverse split.

  • EMJX

    Acquisition completed prior to this balance-sheet update, referenced as part of the capitalization and debt elimination story.

  • Kent Cunningham

    CEO quoted stating the company has entered 2H 2026 with one of its strongest balance sheets.

Related articles

$SRXHMed

SRX Global Inc. (SRXH): Results of Operations and Financial Condition

SRX Global Inc. (SRXH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SRX GLOBAL INC. ANNOUNCES FISCAL THIRD QUARTER 2026 FINANCIAL RESULTS Net Asset Value (“NAV”) of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricte

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$SRXHMed

SRx Health Solutions, Inc.: SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences

SRX Global (NYSE American: SRXH) said it made a strategic investment in clinical-stage biodefense company ARMR Sciences. ARMR’s lead candidate ARMR-100, in a Phase 1/2 trial, recently reported generating an anti-fentanyl immune response in humans with favorable safety data. The company plans to start evaluating protection against fentanyl later in 2026.

$SRXHMedAI 8/10

SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)

SRx Health Solutions (NYSE American: SRXH) said it acquired 4.99% of Smartkem (NASDAQ: SMTK) via a shelf take down, and also bought convertible preferred securities in a non-brokered private placement, according to the company. SRx noted it filed an SEC Form S-4 to register shares for the proposed transaction involving EMJ Crypto Technologies (EMJX).

$AVGOHighAI 9/10

Broadcom (AVGO) Nears $70B Debt Financing Deal, Sources Say

Broadcom (AVGO) is in talks to raise $70B-$80B in debt for AI chip financing, with Blackstone and Apollo involved. The deal supports AI companies like Anthropic and extends a June partnership. Shares rose 1% on the news. The financing structure keeps debt off Broadcom's balance sheet, but the company guarantees part of it. The deal's size and terms remain fluid, with potential execution risks.